Analysts: Allergan’s Phase II Trial Released Early and 3 More Research Notes to Browse

Allergan (NYSE:AGN): BMO Capital points out that Stage 3 of Allergan’s phase II trial for its anti-VEGF DARPin product was released on sooner than expected. BMO sees this as a positive for the company and has an Outperform rating on the stock with a $118 price target.


Autonation (NYSE:AN): Credit Suisse has upgraded Autonation to Outperform from Neutral due to low valuation and leverage to the impending parts and service cycle. The price target has been raised to $53 from $50.

an (NASDAQ:OSTK): Bank of America Merrill Lynch has downgraded two notches to Underperform from Buy due to rich valuation, lack of consistency, and increased customer growth concerns. However, the price target has increased to $23 from $20.


Capital One (NYSE:COF): CLSA has raised its price target on Capital One to $76 from $68 following the approval of the new $1 billion share repurchase authorization. It rates the shares at Buy.


Don’t Miss: Gallup: U.S. Workers Say Job Creation is at a Five-Year High.